QQ客服 官方微博 反馈留言

	Olaparib monotherapy versus chemotherapy for patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: Asian subgroup analysis from the phase III OlympiAD trial
	Li, Wei; Im, Seock-Ah; Xu, Binghe; Robson, Mark; Ouyang, Quchang; Yeh, Dah-Cherng; Iwata, Hiroji; Park, Yeon-Hee; Sohn, Joo Hyuk; Tseng, Ling-Min
刊名	CANCER RESEARCH
	2018
卷号	78期号:4
ISSN号	0008-5472
URL标识	查看原文
语种	英语
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/3534468
专题	吉林大学白求恩第一医院
推荐引用方式 GB/T 7714	Li, Wei,Im, Seock-Ah,Xu, Binghe,et al. Olaparib monotherapy versus chemotherapy for patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: Asian subgroup analysis from the phase III OlympiAD trial[J]. CANCER RESEARCH,2018,78(4).
APA	Li, Wei.,Im, Seock-Ah.,Xu, Binghe.,Robson, Mark.,Ouyang, Quchang.,...&Masuda, Norikazu.(2018).Olaparib monotherapy versus chemotherapy for patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: Asian subgroup analysis from the phase III OlympiAD trial.CANCER RESEARCH,78(4).
MLA	Li, Wei,et al."Olaparib monotherapy versus chemotherapy for patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: Asian subgroup analysis from the phase III OlympiAD trial".CANCER RESEARCH 78.4(2018).

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。